PubMed=16256156; DOI=10.1016/j.rvsc.2005.09.005
Thamm D.H., Dickerson E.B., Akhtar N., Lewis R., Auerbach R., Helfand S.C., MacEwen E.G.
Biological and molecular characterization of a canine hemangiosarcoma-derived cell line.
Res. Vet. Sci. 81:76-86(2006)

PubMed=17338158; DOI=10.1111/j.1939-1676.2007.tb02936.x
U'Ren L.W., Biller B.J., Elmslie R.E., Thamm D.H., Dow S.W.
Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma.
J. Vet. Intern. Med. 21:113-120(2007)

PubMed=21908323; DOI=10.1177/1040638711408064
O'Donoghue L.E., Rivest J.P., Duval D.L.
Polymerase chain reaction-based species verification and microsatellite analysis for canine cell line validation.
J. Vet. Diagn. Invest. 23:780-785(2011)

PubMed=22594682; DOI=10.1111/j.1476-5829.2012.00335.x
Lyles S.E., Milner R.J., Kow K., Salute M.E.
In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines.
Vet. Comp. Oncol. 10:223-235(2012)

PubMed=22849686; DOI=10.2460/ajvr.73.8.1252
Urbasic A.S., Hynes S., Somrak A.J., Contakos S., Rahman M.M., Liu J., MacNeill A.L.
Oncolysis of canine tumor cells by myxoma virus lacking the serp2 gene.
Am. J. Vet. Res. 73:1252-1261(2012)

PubMed=27257868; DOI=10.1371/journal.pone.0156689; PMCID=PMC4892608
Maeda J., Froning C.E., Brents C.A., Rose B.J., Thamm D.H., Kato T.A.
Intrinsic radiosensitivity and cellular characterization of 27 canine cancer cell lines.
PLoS ONE 11:E0156689-E0156689(2016)

PubMed=26842912; DOI=10.1111/vco.12197
Hartley G., Faulhaber E.A., Caldwell A., Coy J., Kurihara J.N., Guth A., Regan D.P., Dow S.W.
Immune regulation of canine tumour and macrophage PD-L1 expression.
Vet. Comp. Oncol. 15:534-549(2017)

PubMed=31175136; DOI=10.1158/1535-7163.MCT-18-1346; PMCID=PMC6679748
Das S., Idate R., Cronise K.E., Gustafson D.L., Duval D.L.
Identifying candidate druggable targets in canine cancer cell lines using whole-exome sequencing.
Mol. Cancer Ther. 18:1460-1471(2019)